Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Liquidia Technologies (LQDA – Research Report). The associated price target remains the same with $35.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Liquidia Technologies’ strategic legal actions and its potential market advantages. The recent patent infringement lawsuit filed by Liquidia against United Therapeutics is a significant move, as it addresses the alleged infringement on Liquidia’s ‘494 patent related to specific dosage levels of treprostinil. This legal action highlights Liquidia’s proactive approach in protecting its intellectual property, which could lead to potential damages if the court rules in their favor.
Additionally, the ‘494 patent, which covers dry powder formulations at higher dosage levels, is distinct from previously invalidated patents, suggesting a stronger position for Liquidia. Despite the ongoing legal battles, the launch timelines for Liquidia’s product, Yutrepia, remain unaffected, indicating operational stability. These factors, combined with the company’s financial metrics and market positioning, contribute to the Buy rating, reflecting confidence in Liquidia’s future performance.
In another report released on April 10, Needham also maintained a Buy rating on the stock with a $25.00 price target.